Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian
- PMID: 25224030
- PMCID: PMC4293332
- DOI: 10.1002/cncr.29041
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian
Erratum in
-
Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK and Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269-275.Cancer. 2015 Jul 15;121(14):2474-5. doi: 10.1002/cncr.29357. Epub 2015 Apr 17. Cancer. 2015. PMID: 26132389 No abstract available.
Abstract
Background: Previous studies have reported additional cancers associated with BRCA mutations; however, the type, magnitude of risk, and sex differences remain to be clarified. The purpose of this study was to evaluate the incidence of cancers other than breast and ovarian cancer in known mutation carriers.
Methods: An institutional review board-approved study identified 1072 patients who had genetic counseling at the authors' institution and tested positive for a deleterious BRCA mutation. The expected number of cancer cases was calculated from the number of individuals in the study sample multiplied by the cancer incidence rates for the general population. The expected and observed numbers of cases were calculated in 5-year intervals to accommodate different age-related incidence rates. Standardized incidence ratios (SIRs) for each cancer type were calculated.
Results: Among the 1072 mutation carriers, 1177 cancers of 30 different cancer types were identified. Individuals with a BRCA1 mutation did not have a significant increase in cancers other than breast and ovarian cancer; however, a trend in melanoma was observed. Individuals with a BRCA2 mutation had significantly higher numbers of observed cases versus expected cases for pancreatic cancer in both men and women (SIR, 21.7; 95% confidence interval [CI], 13.1-34.0; P < .001) and for prostate cancer in men (SIR, 4.9; 95% CI, 2.0-10.1; P = .002).
Conclusions: The results of this study uphold the current recommendations for hereditary breast and ovarian cancer screening of cancers other than breast and ovarian cancer by the National Comprehensive Cancer Network. Larger cohorts and collaborations are needed to further verify these findings.
Keywords: BRCA mutation; genetics; hereditary breast and ovarian cancer syndrome; pancreatic cancer; prostate cancer.
© 2014 American Cancer Society.
Figures
Similar articles
-
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.Clin Cancer Res. 2002 Dec;8(12):3776-81. Clin Cancer Res. 2002. PMID: 12473589
-
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.Br J Cancer. 2009 Jan 27;100(2):421-5. doi: 10.1038/sj.bjc.6604830. Epub 2008 Dec 16. Br J Cancer. 2009. PMID: 19088722 Free PMC article.
-
Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.Breast Cancer Res Treat. 2010 Jan;119(2):409-14. doi: 10.1007/s10549-009-0611-y. Breast Cancer Res Treat. 2010. PMID: 19885732
-
Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.Breast J. 2020 Aug;26(8):1520-1527. doi: 10.1111/tbj.13970. Epub 2020 Jul 11. Breast J. 2020. PMID: 32652823 Review.
-
BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.Radiology. 2019 Jun;291(3):554-569. doi: 10.1148/radiol.2019181814. Epub 2019 Apr 30. Radiology. 2019. PMID: 31038410 Review.
Cited by
-
New treatment option for ovarian cancer: PARP inhibitors.Gynecol Oncol Res Pract. 2016 Feb 26;3:3. doi: 10.1186/s40661-016-0024-7. eCollection 2016. Gynecol Oncol Res Pract. 2016. PMID: 27231574 Free PMC article. Review.
-
A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine.Oncotarget. 2016 Aug 16;7(33):52888-52899. doi: 10.18632/oncotarget.9184. Oncotarget. 2016. PMID: 27167109 Free PMC article.
-
Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer.J Natl Cancer Inst. 2024 Jun 7;116(6):911-919. doi: 10.1093/jnci/djae030. J Natl Cancer Inst. 2024. PMID: 38366028 Free PMC article.
-
Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?Front Cell Dev Biol. 2018 Sep 5;6:71. doi: 10.3389/fcell.2018.00071. eCollection 2018. Front Cell Dev Biol. 2018. PMID: 30234108 Free PMC article. Review.
-
A Guide to PIN1 Function and Mutations Across Cancers.Front Pharmacol. 2019 Jan 22;9:1477. doi: 10.3389/fphar.2018.01477. eCollection 2018. Front Pharmacol. 2019. PMID: 30723410 Free PMC article.
References
-
- Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71. - PubMed
-
- Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789–792. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous